Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 3/2005

01-03-2005 | Controversies–Against

Is whole-body FDG-PET valuable for health screening?

Authors: Matthias Weckesser, Otmar Schober

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2005

Login to get access

Excerpt

The idea of using imaging for whole-body cancer screening is alluring. Every nuclear medicine physician working with 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) has observed patients with malignancies unrelated to the referral diagnosis. In a series of such clinically unexpected results, Agress and Cooper showed that ‘incidental’ does not mean ‘negligible’; considerable pathology, especially in the colon, may be detected [1]. These observations suggest the use of FDG-PET for health screening. The justification for such an approach, however, is far from clear, and many prerequisites will have to be met before FDG-PET can be recommended for this purpose. …
Literature
1.
Agress H Jr, Cooper BZ. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology 2004;230:417–22.
2.
3.
Bayes T. An essay toward solving a problem in the doctrine of chances. Philos Trans R Soc Lond 1763;53:370–418.
4.
Drenth JP, Nagengast FM, Oyen WJ. Evaluation of (pre-)malignant colonic abnormalities: endoscopic validation of FDG-PET findings. Eur J Nucl Med 2001;28:1766–9.CrossRef
5.
Yasuda S, Fujii H, Nakahara T, Nishiumi N, Takahashi W, Ide M, et al. 18F-FDG PET detection of colonic adenomas. J Nucl Med 2001;42:989–92.
6.
Patz EF Jr, Goodman PC, Bepler G. Screening for lung cancer. N Engl J Med 2000;30(343):1627–33.CrossRef
7.
Chen YK, Kao CH, Liao AC, Shen YY, Su CT. Colorectal cancer screening in asymptomatic adults: the role of FDG PET scan. Anticancer Res 2003;23:4357–61.
8.
Shen YY, Su CT, Chen GJ, Chen YK, Liao AC, Tsai FS. The value of 18F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening. Neoplasma 2003;50:217–21.
9.
Yasuda S, Ide M, Fujii H, Nakahara T, Mochizuki Y, Takahashi W, et al. Application of positron emission tomography imaging to cancer screening. Br J Cancer 2000;83:1607–11.CrossRef
10.
Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002;105:310–5.CrossRefPubMed
11.
Smith JA, Andreopoulou E. An overview of the status of imaging screening technology for breast cancer. Ann Oncol 2004;15:I18–26.CrossRef
12.
Ell PJ. News and views. Eur J Nucl Med Mol Imaging 2005;31:127–38.
13.
Deloar HM, Fujiwara T, Shidahara M, Nakamura T, Watabe H, Narita Y, et al. Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-d-glucose using whole-body positron emission tomography and magnetic resonance imaging. Eur J Nucl Med 1998;25:565–74.CrossRef
14.
International Commission on Radiological Protection, Report No. 60 (1991) Recommendations of the International Commission on Radiological Protection.
15.
Pastorino U, Bellomi M, Landoni C, De Fiori E, Arnaldi P, Picchio M, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet 2003;362:593–97.CrossRefPubMed
Metadata
Title
Is whole-body FDG-PET valuable for health screening?
Authors
Matthias Weckesser
Otmar Schober
Publication date
01-03-2005
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2005
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-005-1775-2

Other articles of this Issue 3/2005

European Journal of Nuclear Medicine and Molecular Imaging 3/2005 Go to the issue

Original Article

Quantitation of dopamine transporter blockade by methylphenidate: first in vivo investigation using [123I]FP-CIT and a dedicated small animal SPECT

Announcements

March 2005

Original Article

Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death

Letter to the Editor

Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines

Book Review

How does MRI work? An introduction to the physics and function of Magnetic Resonance Imaging. 2003. D. Weishaupt, V.D. Köchli, B.

News & Views

March 2005